FDA Warning on Xylazine: Mitigating Human Risk | by: Sumeet Singh, Founder & Chairman | Article Posted: November 6, 2023 | The U.S. Food and Drug Administration (FDA) has issued a warning regarding mitigating risks from human Xylazine exposure. FDA has not...
Pharma Solutions and QPharma Announce Partnership for Comprehensive DEA Compliance Software Solution Pharmaceutical compliance partnership allows...
DEA Insights from the 2018 DEA Diversion Conference The DEA hosted a conference in San Antonio, TX that addressed multiple aspects of how those that...
DEA Limits Quotas Key Reductions, 2019 versus 2018 per HDA: ANPP 88% Codeine (for conversion) 90% Dihydrocodeine 90% Dihydromorphine* 74% Fentanyl...
DEA Makes Moves 2018 Series, Part 1: Pharmacies & Red Flags In recent months, the DEA has begun ramping up its enforcement efforts across the...
4th Largest US Wholesaler has DEA Registration Suspended In an attempt to rein in the Opioid Epidemic, it seems that recently, the DEA has become...
DEA Offers a Tiny Peak Behind the ARCOS Curtain DEA has “enhanced” its ARCOS online reporting system to help distributors and manufacturers know...
